Beyond PSMA: A Dual-Target Radioligand Takes Aim at FAP and αvβ3
Most radioligand therapies rely on a single molecular target. INN02 takes a different approach, combining two targets in the same molecule: fibroblast activation protein (FAP) and integrin αvβ3, both found in the tumour microenvironment. The same compound can be labelled with gallium-68 for PET imaging or lutetium-177 for therapy, creating a true theranostic platform. In […]
